Tillgänglig läkemedelsinformation i Sverige
Kontakta ossFAQ

QL04AC - Interleukinhämmare

  1. QL01Antineoplastiska medel

  2. QL02Endokrinterapi

  3. QL03Immunstimulerande medel

  4. QL04Immunsuppressiva medel

  1. QL04AImmunsuppressiva medel

  1. QL04AASelektiva immunsuppressiva medel

  2. QL04ABTumörnekrosfaktor alfa (TNF-alfa) hämmare

  3. QL04ACInterleukinhämmare

  4. QL04ADKalcineurinhämmare

  5. QL04AESfingosin-1-fosfat (S1P) receptormodulatorer

  6. QL04AFJanus-associerat kinas (JAK) hämmare

  7. QL04AGMonoklonala antikroppar

  8. QL04AHMammalian target of rapamycin (mTOR) kinashämmare

  9. QL04AJKomplementhämmare

  10. QL04AKDihydroorotatdehydrogenas (DHODH) hämmare

  11. QL04AXÖvriga immunsuppressiva medel

  1. QL04AC01Daklizumab

  2. QL04AC02Basiliximab

  3. QL04AC03Anakinra

  4. QL04AC04Rilonacept

  5. QL04AC05Ustekinumab

  6. QL04AC07Tocilizumab

  7. QL04AC08Kanakinumab

  8. QL04AC09Briakinumab

  9. QL04AC10Sekukinumab

  10. QL04AC11Siltuximab

  11. QL04AC12Brodalumab

  12. QL04AC13Ixekizumab

  13. QL04AC14Sarilumab

  14. QL04AC15Sirukumab

  15. QL04AC16Guselkumab

  16. QL04AC17Tildrakizumab

  17. QL04AC18Risankizumab

  18. QL04AC19Satralizumab

  19. QL04AC20Netakimab

  20. QL04AC21Bimekizumab

  21. QL04AC22Spesolimab

  22. QL04AC23Olokizumab

  23. QL04AC24Mirikizumab

  24. QL04AC25Levilimab

  25. QL04AC26Goflikicept